Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer. (2nd November 2018)

• Record Type: Journal Article
• Authors: Leal, Alexis D.; Krishnamurthy, Anuradha; Head, Lia; Messersmith, Wells A.
• Is Part Of: Expert opinion on investigational drugs. Volume 27:Number 11(2018)
• Page Start: 901
• Page End: 916
• Publication Date: 2018-11-02
• Subjects: Adenocarcinoma -- antibody drug conjugate -- cholangiocarcinoma -- colorectal cancer -- drug conjugates -- esophageal cancer -- gastric cancer -- gastrointestinal malignancies -- immunoconjugates -- pancreatic cancer; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2018.1541085
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction : Antibody drug conjugates (ADCs) represent a developing class of anticancer therapeutics which are designed to selectively deliver a cytotoxic payload to tumors, while limiting systemic toxicity to healthy tissues. There are several ADCs which are currently in various stages of clinical development for the treatment of gastrointestinal malignancies. Areas covered : We discuss the biologic rationale and review the clinical experience with ADCs in the treatment of gastrointestinal malignancies, summarizing the pre-clinical and phase I/II clinical trial data that have been completed or are ongoing. Expert opinion : While there have been significant advances in the development of ADCs since they were first introduced, several challenges remain. These challenges include (i) the selection of an ideal antigen target which is tumor specific and internalized upon binding, (ii) selection of an antibody which has high affinity for its antigen target and low immunogenicity, (iii) selection of a potent payload which is cytotoxic at sub-nanomolar concentrations, and (iv) optimal design of a linker to confer ADC stability with limited off-site toxicity. Efforts are ongoing to address these issues and innovate the ADC technology to improve the safety and efficacy of these agents.